EXPRESSION PROFILING OF ENDOSOMAL PATHWAYS IN AD
AD 内体途径的表达谱
基本信息
- 批准号:6920489
- 负责人:
- 金额:$ 28.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-04-01 至 2010-03-31
- 项目状态:已结题
- 来源:
- 关键词:Alzheimer&aposs diseaseDowns syndromeautophagybiomarkercellular pathologydentate gyrusendocytosisfibroblastsgene expressiongene expression profilinggenetically modified animalsgranule cellhuman tissuelaboratory mouselaser capture microdissectionlysosomesmicroarray technologymolecular pathologyneuritic plaquesneurofibrillary tanglesneurogeneticsneuronsneuropathologypostmortempyramidal cellstissue /cell culturevesicle /vacuole
项目摘要
The aim of this proposal is to delineate antecedent cellular and molecular events that lead to the dysfunction of the endocytic, autophagic, and lysosomal systems (EALS), the earliest cellular disturbances known to occur in sporadic Alzheimer's disease (AD). The design is to assess gene expression levels within vulnerable populations while avoiding potential contamination from other cell types. Gene expression is assayed in neurons with early endosomal abnormalities, the first sign of AD-related responses, as compared to not-as-yet affected neighbors and to less vulnerable neuronal populations. A "molecular fingerprint" of human hippocampal neurons and neocortical neurons, mouse hippocampal and neocortical neurons, and fibroblasts is performed on human postmortem brains, a mouse model of Down's syndrome (Ts21) termed Ts65Dn, and in cultured cells. In this manner, cDNA array analysis is applied systematically to characterize
gene expression changes at the inception of EALS pathology relative to spared neurons in these brains and to unaffected neurons in normal control brains. The experimental design entails microaspiration of identified neuronal populations followed by a novel single cell RNA amplification methodology developed in the laboratory of the Project Leader combined with custom-designed cDNA array analysis. Aim 1 consists of assessment of select neuronal populations from human postmortem brains. Aim 2 evaluates individual neuronal populations obtained from Ts65Dn and diploid mice. Aim 3 consists of gene expression analysis of
cultured Ts21 fibroblasts with App levels knocked down via small interference RNA (siRNA). Aim 4 utilizes siRNA technology to knockdown other genes in the trisomic region for subsequent cDNA array analysis. This state-of-the-art paradigm enables an extensive, concurrent representation of hundreds of genes in selectively vulnerable and relatively spared cell types to neurodegeneration that represent some of the earliest pathological changes observed in AD and Ts21 brains at defined stages of pathology evolution.
这项建议的目的是描绘导致内吞、自噬和溶酶体系统(EALS)功能障碍的前驱细胞和分子事件,EALS是已知在散发性阿尔茨海默病(AD)中发生的最早的细胞紊乱。这项设计是为了评估脆弱人群中的基因表达水平,同时避免来自其他细胞类型的潜在污染。在有早期内体异常的神经元中检测基因表达,这是AD相关反应的第一个迹象,与尚未受到影响的邻居和较不脆弱的神经元群体进行比较。人类海马神经元和新皮质神经元、小鼠海马神经元和新皮质神经元以及成纤维细胞的“分子指纹”在人死后的大脑、唐氏综合症(Ts21)小鼠模型Ts65Dn和培养细胞中进行。以此方式,系统地应用cDNA阵列分析来表征
在EALS病理开始时,相对于这些大脑中的备用神经元和正常对照大脑中未受影响的神经元,基因表达发生了变化。实验设计需要对已识别的神经元群体进行显微抽吸,然后在项目负责人的实验室中开发出一种新的单细胞RNA扩增方法,并结合定制设计的cDNA阵列分析。目标1包括从人死后大脑中选择神经元群体的评估。目的2评估从Ts65Dn和二倍体小鼠中获得的单个神经元群体。目标3由基因表达分析组成
培养的Ts21成纤维细胞通过小干扰RNA(SiRNA)下调App水平。AIM 4利用siRNA技术敲除三体区域中的其他基因,用于后续的cDNA阵列分析。这一最先进的范例能够在选择性脆弱和相对较少发生神经变性的细胞类型中广泛、同时表示数百个基因,这些细胞类型代表了AD和Ts21大脑在确定的病理进化阶段观察到的一些最早的病理变化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
STEPHEN D GINSBERG其他文献
STEPHEN D GINSBERG的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('STEPHEN D GINSBERG', 18)}}的其他基金
Septhohippocamal connectome dysfunction in Down syndrome associated with Alzheimer’s disease pathophysiology
与阿尔茨海默病病理生理学相关的唐氏综合症中的隔海马连接体功能障碍
- 批准号:
10595384 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Cellular and Molecular Medial Temporal Lobe Pathology in Elderly PreMCI subjects
老年 PreMCI 受试者的细胞和分子内侧颞叶病理学
- 批准号:
8574411 - 财政年份:2013
- 资助金额:
$ 28.6万 - 项目类别:
Cellular and Molecular Medial Temporal Lobe Pathology in Elderly PreMCI subjects
老年 PreMCI 受试者的细胞和分子内侧颞叶病理学
- 批准号:
8962197 - 财政年份:2013
- 资助金额:
$ 28.6万 - 项目类别:
Cellular and Molecular Medial Temporal Lobe Pathology in Elderly PreMCI subjects
老年 PreMCI 受试者的细胞和分子内侧颞叶病理学
- 批准号:
9293192 - 财政年份:2013
- 资助金额:
$ 28.6万 - 项目类别:
Neuronal basis of sensory processing dysfunction in schizophrenia
精神分裂症感觉处理功能障碍的神经元基础
- 批准号:
8105222 - 财政年份:2010
- 资助金额:
$ 28.6万 - 项目类别:
Single Cell Gene Expression Profiling in hTau Mice
hTau 小鼠的单细胞基因表达谱
- 批准号:
6966709 - 财政年份:2005
- 资助金额:
$ 28.6万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Pathophysiological mechanisms of hypoperfusion in mouse models of Alzheimer?s disease and small vessel disease
阿尔茨海默病和小血管疾病小鼠模型低灌注的病理生理机制
- 批准号:
10657993 - 财政年份:2023
- 资助金额:
$ 28.6万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10381163 - 财政年份:2022
- 资助金额:
$ 28.6万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 28.6万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 28.6万 - 项目类别:
Interneurons as early drivers of Huntington´s disease progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10518582 - 财政年份:2022
- 资助金额:
$ 28.6万 - 项目类别:
Interneurons as Early Drivers of Huntington´s Disease Progression
中间神经元是亨廷顿病进展的早期驱动因素
- 批准号:
10672973 - 财政年份:2022
- 资助金额:
$ 28.6万 - 项目类别:
Social Connectedness and Communication in Parents with Huntington''s Disease and their Offspring: Associations with Psychological and Disease Progression
患有亨廷顿病的父母及其后代的社会联系和沟通:与心理和疾病进展的关联
- 批准号:
10585925 - 财政年份:2022
- 资助金额:
$ 28.6万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 28.6万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 28.6万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 28.6万 - 项目类别: